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BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF
ROSIGLITAZONE IN THE TREATMENT OF TYPE-2 DIABETES.
THE ITALIAN NHS PERSPECTIVE
Novelli M,Avallone A, Frizzo V, Bamﬁ F
GlaxoSmithKline,Verona,VR, Italy
OBJECTIVES: To evaluate the budget impact on the Italian NHS
of rosiglitazone based treatment strategies, compared to current
therapy. METHODS: Estimated target population for alternative
treatments was based on algorithms previously reported*. Three
groups of patients were identiﬁed to compare alternative treat-
ment strategies: 1) Rosiglitazone monotherapy vs. SU monother-
apy; 2) Rosiglitazone + metformin vs. SU + metformin; and 3)
Siglitazone + SU vs. insulin alone or in association with SU. The
perspective used was that of the Italian NHS. Time horizon was
one year. Costs/patient/year considered were: drug acquisition
costs; glycaemia self-monitoring costs; severe hypoglycaemias
costs; and clinical tests costs (according to therapy). Glycaemia
self-monitoring assumptions were based on AMD (Italian Asso-
ciation of Diabetologists) guidelines. Sensitivity analysis was per-
formed to test the robustness of the assumptions made and their
inﬂuence on the results. RESULTS: The epidemiological algo-
rithms assigned 19.84% of patients to group 1, 37.8% to group
2 and 42.36% to group 3. Treatment costs/patient/year were:
group 1–€459,91 for rosiglitazone vs. €469,06 for SU; group
2–€531,06 for rosiglitazone + metformin vs. €540,20 for SU +
metformin; group 3–€749,44 for rosiglitazone + SU vs.
€1.258,11 for insulin + SU and €1.832,97 for insulin alone. For
a hypothetical cohort of 10.000 patients, total costs were: group
1—rosiglitazone €912,460.31 vs. SU €930,581.45; group 2—
rosiglitazone + metformin €2,007,419.76 vs. SU + metformin
€2,041,944.92; group 3—rosiglitazone + SU €3,174,623.90,
insulin + SU €1,862,082.89 and insulin alone €5,051,558.94.
Total costs of Rosiglitazone based therapy were €6,094,503.97
vs. €9,886,168.20 of current treatments. CONCLUSIONS:
Rosiglitazone, when compared to alternative treatment, may
offer potential savings to the Italian NHS estimated by our model
in €3,791,664 every 10,000 diabetics per year. Savings were
mainly related to a reduction in costs of glucose self-monitoring
and insulin administration.* Drug utilization of glitazones in
Italy. ISPOR, 7th Annual European Congress.
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OBJECTIVES: To estimate incremental drug costs and savings
resulting from hypoglycemia risk reduction produced by insulin
Glargine compared to NPH insulin from payers perspective in
Poland. METHODS: Epidemiological data and expert panel
were used to evaluate the number of patients eligible for insulin
Glargine treatment in Poland. Logistic model of switching rate
from NPH insulin to insuline Glargine was developed for 3 years
time horizon for diabetes patients according to NICE guidelines.
Net drug costs reﬂect incremental acquisition costs per i.u. as
well as difference between mean daily doses of insulin Glargine
and NPH. Savings resulting from hypoglycemia risk reduction
were estimated based on literature review and unit cost of hypo-
glycemic event treatment (payers’ perspective; event associated
with hospitalization or ER visit). RESULTS: Number of patients
eligible for insuline Glargine treatment was estimated at 64 608
patients accounting for 5.48% of all diabetic patients in Poland.
Mean annual drug costs were estimated at 24.5mln EUR (PPP
value) while savings resulting from hypoglycemia risk reduction
at 4mln EUR. Subgroup showed for patients with annual hypo-
glycemia risk reduction associated with insulin Glargine 68.4%
drug acquisition expenditures, which are balanced by hypo-
glycemia treatment savings. CONCLUSIONS: Insulin Glargine
treatment was found to be budgetary neutral from payers’ per-
spective for patients with very high risk of hypoglycemia in
Poland.
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OBJECTIVES: It is extremely difﬁcult to assess the prevalence,
the total costs of Diabetes mellitus and the impact of self mea-
surement of blood glucose (SMBG) for the German health care
system. The last sound assessment of the total costs is based on
the CODE-2 study, although this study reﬂects the situation in
1998. METHODS: In this analysis we assessed the total costs of
diabetes mellitus type-2 and self measurement of blood glucose
(SMBG) for the German health care system in the year 2004,
based on the analysis of a retrospective, multicenter trial carried
out recently, dealing with the impact of SMBG on long term
patient outcomes. Our assessment is based on costs for 18 dia-
betes related complications (including surgical interventions),
follow-up-costs for these complications, costs for outpatient
physician services, cost of antidiabetic and additional pharma-
ceutical treatment and costs for strips and lancets for patients
performing SMBG. RESULTS: Overall, yearly costs for the treat-
ment of diabetes mellitus type-2 and its complications amounts
to €3489 per patient. This equals to 4.6% to 8.2% of the
German health care expenditure, in function of the estimated
prevalence of the disease in Germany. The cost difference
between the cohort with and without SMBG was not essential
(€276 higher costs in the cohort with SMBG). This cost differ-
ence should be connected with a reduction of mortality from 
4.6 to 2.7% and a reduction of non-fatal endpoints from 10.4
to 7.2% for the Non-SMBG and SMBG group respectively
reported in the underlaying study. CONCLUSIONS: From a
public health standpoint, prevention of diabetes mellitus or at
minimum prevention of its complications by optimizing glucose
metabolism should be given highest priority in times of limited
resources for health care. SMBG may be a valuable tool to
achieve this target.
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OBJECTIVE: The diabetic foot is a complex late complication,
it is difﬁcult to treat and has severe impact on quality of life and
causes an enormous ﬁnancial burden for society. Aim of this
